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Background: Tumor hypoxia is one of the features of tumor microenvironment that contributes to chemoresistance.
miRNAs have recently been shown to play important roles in tumorigenesis and drug resistance. Moreover, hypoxia
also regulates the expression of a series of miRNAs. However, the interaction between chemoresistance, hypoxia and
miRNAs has not been explored yet. The aim of this study is to understand the mechanisms activated/inhibited by
miRNAs under hypoxia that induce resistance to chemotherapy-induced apoptosis.
Methods: TaqMan low-density array was used to identify changes in miRNA expression when cells were exposed to
etoposide under hypoxia or normoxia. The effects of miR-196b overexpression on apoptosis and cell proliferation were
studied in HepG2 cells. miR-196b target mRNAs were identified by proteomic analysis, luciferase activity assay, RT-qPCR
and western blot analysis.
Results: Results showed that hypoxia down-regulated miR-196b expression that was induced by etoposide. miR-196b
overexpression increased the etoposide-induced apoptosis and reversed the protection of cell death observed under
hypoxia. By a proteomic approach combined with bioinformatics analyses, we identified IGF2BP1 as a potential target
of miR-196b. Indeed, miR-196b overexpression decreased IGF2BP1 RNA expression and protein level. The IGF2BP1
down-regulation by either miR-196b or IGF2BP1 siRNA led to an increase in apoptosis and a decrease in cell viability
and proliferation in normal culture conditions. However, IGF2BP1 silencing did not modify the chemoresistance
induced by hypoxia, probably because it is not the only target of miR-196b involved in the regulation of apoptosis.
Conclusions: In conclusion, for the first time, we identified IGF2BP1 as a direct and functional target of miR-196b and
showed that miR-196b overexpression reverses the chemoresistance induced by hypoxia. These results emphasize that
the chemoresistance induced by hypoxia is a complex mechanism.
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Resistance mechanisms remain a key challenge in the fight
against cancer. Acquired drug resistance is of major clinical
significance both for conventional and targeted therapies
[1]. The first cause of therapeutic failure results from genetic
alterations existing before treatment. Several researchers
have evidenced the role of epigenetic changes [2,3] as well
as the influence of the tumor microenvironment [4] on che-
moresistance. One of the main characteristics of tumor* Correspondence: carine.michiels@unamur.be
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unless otherwise stated.microenvironment is the presence of hypoxic areas. Hyp-
oxia is known to affect gene expression not only by regulat-
ing transcription [5] but also by epigenetic changes [6].
Furthermore, hypoxia and the adaptive responses of cancer
cells play an important role in cancer progression [5].
Tumor microenvironment also strongly modulates the sen-
sitivity of cancer cells to therapies. Previous results from our
group showed that hypoxia protects tumor cells from apop-
tosis induced by several chemotherapeutic agents [7,8]. This
protective effect has also been demonstrated by others,
using other cell lines and other drugs [9,10] suggesting a
general process.l. This is an Open Access article distributed under the terms of the Creative
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non-coding RNAs. In mammals, mature miRNAs regu-
late gene expression by directly degrading mRNA or by
suppressing protein translation through binding to the
3′ untranslated region (3′UTR) of targeted gene tran-
scripts [11]. A single miRNA can target hundreds of
mRNAs and a single mRNA can be influenced by mul-
tiple miRNAs [12,13]. Hence, getting a comprehensive
understanding of the phenotypic effects of miRNAs at
the level of the entire cell might be difficult.
Recent studies have evidenced correlation between the
expression of several miRNAs in tumors and their predict-
ive values. The expression of different miRNAs seems to
correlate with anti-cancer treatment sensitivity: miR-30c,
miR-130a and miR-335 expression is decreased in differ-
ent chemoresistant cell lines while Let-7 g and miR-181b
are associated to a response to anti-metabolic agents such
as 5-fluorouracil (for review [2-4]). Moreover, several miR-
NAs directly influence the sensitivity of tumor cells to an-
ticancer agents. As examples, miR-155 modulates breast
cancer cell sensitivity to doxorubicin, paclitaxel and etopo-
side [5], miR-148a decreases paclitaxel resistance of
prostate cancer cells [14], miR-125b confers paclitaxel re-
sistance in breast cancer cells by decreasing Bcl-2 expres-
sion [15], and the let-7 family of miRNAs inhibits Bcl-xl
expression and potentiates sorafenib-induced apoptosis in
human hepatocarcinoma [16].
In addition to modulate apoptosis, hypoxia also regu-
lates the expression of several miRNAs [17]. Among these
hypoxia-regulated miRNAs, the HIF-responsive miR-210
appears as a ubiquitously expressed hypoxamir [18-20].
If links between hypoxia and chemoresistance, between
hypoxia and changes in miRNA expression and between
miRNAs and chemoresistance have been established, no
study until now has tried to integrate all three. Previous re-
sults from our group showed that hypoxia protects HepG2
cells against etoposide-induced apoptosis [7,8]. In this con-
text, we first analyzed the expression of 365 miRNAs in
HepG2 cells. Among the miRNAs potentially involved in
chemoresistance induced by hypoxia, we identified miR-
196b. Hypoxia decreased the miR-196b expression that was
induced by etoposide. In addition, miR-196b overexpres-
sion reversed the protection induced by hypoxia. Further-
more, we identified IGF2BP1 (insulin-like growth factor 2
RNA binding protein1) as a direct and functional target of
miR-196b. However, IGF2BP1 silencing was not sufficient
to reverse the chemoresistance induced by hypoxia.
Results
Identification of miRNAs differentially expressed in cells
incubated under normoxia or hypoxia with or without
etoposide
In order to explore the role of miRNAs in chemoresis-
tance induced by hypoxia, the expression level of 365miRNAs was compared in HepG2 cells exposed to nor-
moxia or hypoxia with or without etoposide during 16 h.
We identified 11 miRNAs for which expression was dys-
regulated with a fold change higher than 1.5 in cells in-
cubated under normoxia with etoposide when compared
to cells incubated under hypoxia with etoposide. The
expression of 4 miRNAs was significantly up-regulated
in cells incubated under hypoxia with etoposide com-
pared to cells incubated under normoxia with etoposide
(hsa-miR-220, −219, −210, −193a) while the expression
of 7 miRNAs was significantly down-regulated in cells
incubated under hypoxia compared to cells incubated
under normoxia in the presence of etoposide (fold
change > −1.5) (Figure 1A). To confirm the results of the
TaqMan low-density array (TLDA) analysis, RT-qPCR
assays were performed to evaluate miRNAs differentially
expressed (Figure 1B). Among the 11 differentially expressed
miRNAs identified by TLDA, changes in expression for
only 3 miRNAs were validated. Etoposide significantly in-
creased the miR-565 and miR-196b expression and hyp-
oxia significantly decreased the expression of these two
miRNAs induced by etoposide. On the contrary, hypoxia
exposure with etoposide significantly increased miR-210
expression compared to cells incubated under normoxia
with etoposide (Figure 1B). These results were consistent
with the results obtained with the TLDA analysis.
However, miRBase.org indicated that the sequence of
miR-565 is more likely a tRNA fragment and not a
miRNA [21]. Thus, we decided to focus our study on
the involvement of miR-210 and miR-196b in the che-
moresistance induced by hypoxia.
Anti-apoptotic effect of miR-210 overexpression and
pro-apoptotic effect of miR-196b overexpression
We previously evidenced that hypoxia protects HepG2
cells from etoposide-induced apoptosis. In order to inves-
tigate the potential role of miR-196b and miR-210 in the
hypoxia-induced resistance to etoposide, we performed
western blot analysis for apoptotic markers in cells in
which miR-210 or miR-196b was overexpressed by trans-
fection with miRNA precursor (pre-miR). As shown in
Figure 2, hypoxia decreased PARP and caspase 3 cleavage
induced by etoposide both after 24 and 48 h incubation in
the presence of etoposide in untransfected cells.
miR-210 overexpression decreased PARP and caspase
3 cleavage in cells exposed to normoxia with etoposide
for 48 h, reaching level similar than the one observed
in cells exposed to hypoxia with etoposide, in which
miR-210 expression level is high (Figure 2A). These re-
sults were validated by a caspase 3/7 activity assay. Re-
sults showed that miR-210 overexpression significantly
decreased the caspase 3/7 activity in cells incubated
under normoxia with etoposide (Figure 2B). It must be
noted that overexpression of miR-210 by pre-miR-210
Figure 1 miRNA expression profiling in HepG2 cells incubated under normoxia or hypoxia with or without etoposide. Relative
expression of 132 miRNAs was quantified by TLDA (TaqMan Low Density Array) in cells incubated under normoxia (N) or hypoxia (H) with or
without etoposide (E) (50 μM) during 16 h. (A) Ratio of miRNA expression between cells incubated with etoposide under hypoxia in comparison
to normoxia has been calculated. Four miRNAs were detected with an induction fold higher than 1.5 and seven miRNAs with a fold induction
lower than - 1.5. Data were normalized to RNU44 and RNU48 endogenous controls using the threshold cycle method. (B) miRNA-565, −196b
and −210 expression was monitored by conventional TaqMan RT-qPCR in HepG2 cells exposed to normoxia (N) or hypoxia (H) with or without
etoposide (E) (50 μM) during 16 h. The relative expression of miRNA was determined using the threshold cycle method by normalizing to
endogenous RNU44 (means ± 1SD, n = 3). ***: significantly different from normoxia (p < 0.001), #, ###: significantly different from hypoxia
(p < 0.05, p < 0.001), $$$: significantly different from normoxia with etoposide (p < 0.001).
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deed, miR-210 is overexpressed under hypoxia and there
is a strong protective effect of hypoxia on the etoposide-
induced apoptosis. There is no difference in caspase 3
activity level, nor in caspase 3 and PARP cleavage in cells
incubated with etoposide under hypoxia in comparison to
control normoxic cells, so it is very unlikely that increas-
ing miR-210 level could exert its anti-apoptotic function
in these conditions. As our goal was to identify a miRNA
that exerts a modulatory effect of the etoposide-induced
apoptosis under hypoxia, we next focused our interest on
the role of miR-196.miR-196b overexpression strongly increased PARP and
caspase 3 cleavage in cells incubated with etoposide
under normoxia or hypoxia for 24 or 48 h (Figure 2C).
As shown in Figure 2D, miR-196b overexpression in-
duced a significant increase in caspase 3/7 activity. This
activity reached comparable levels in cells incubated
with etoposide under normoxia or hypoxia. Thus, miR-
196b overexpression not only enhanced the apoptosis in-
duced by etoposide under normoxia but also reversed
the hypoxia-induced chemoresistance.
To further confirm the effect of miR-196b in hypoxia-
induced chemoresistance, HepG2 cells were transfected
Figure 2 (See legend on next page.)
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Figure 2 Effect of miR-210 and miR-196b overexpression on the protective effect of hypoxia on the etoposide-induced apoptosis.
HepG2 cells were transfected with pre-miR negative control (pre-miR CTL-), pre-miR-210 or pre-miR-196b (50 nM) during 24 h or 48 h and then
cells were incubated under normoxia (N) or hypoxia (H) with or without etoposide (E) (50 μM) during 16 h. (A, C) Cleaved caspase 3 and cleaved
PARP were detected in total cell extracts by western blotting analysis, using specific antibodies. Immunodetection of α-tubulin was used to assess
the total amount of proteins loaded on the gel. Numbers correspond to the quantification of the abundance of protein of interest normalized to
the abundance of α-tubulin. (B, D) 48 h post-transfection, the caspase 3/7 activity was assayed by measuring free AFC released from the cleavage
of the caspase 3/7 substrate Ac-DEVD-AFC. Results are expressed in fluorescence intensity, as means ± 1 SD (n = 3). *, **, ***: (p < 0.05, p < 0.01,
p < 0.001), °, °°, °°°: significantly different from untransfected cells (Cells) (p < 0.05, p < 0.01, p < 0.001), $$$: significantly different from pre-miR
negative control transfected cells (p < 0.001) respectively for each group (N, H, NE, HE).
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the miR-196b expression. However, by using several
LNA negative controls (LNA CTL- #1, LNA CTL- #2 or
a mix of LNA CTL- #1 + #2), we observed that LNA
negative controls had a strong impact on apoptotic
markers studied (data not shown). It was thus impossible
to interpret the results obtained with LNA-miR-196b.
Taken together, these results showed that miR-196b
displays a pro-apoptotic function.
Identification of miR-196b targets by proteomic analysis
To unravel the potential role of miR-196b in HepG2
cells and to identify targets of miR-196b, we used a
proteomic approach. HepG2 cells were transfected with
pre-miR-196b or pre-miR negative control for 24 h.
Cells were then harvested, lysed and subjected to subcel-
lular fractionation to recover the cytosolic fraction. Rela-
tive protein abundance differences between negative
control cells and cells that overexpress pre-miR-196b
were then analyzed by 2D-DIGE gels in four independ-
ent replicates (Figure 3). Figure 3A shows a pair of rep-
resentative 2-DE gel images of HepG2 cells transfected
to pre-miR negative control compared to pre-miR-196b.
Proteins from spots with significant changes in inten-
sities (p < 0.05 up- or down-regulated) were cut out for
identification by mass spectrometry. Thirty four spots
differentially abundant were detected, of which 13 spots
were up-regulated and 21 spots were down-regulated.
The complete list of the 172 proteins identified by mass
spectrometry is detailed in Additional file 1. We next
compared the list of differentially expressed proteins
from our proteomic study to the respective list of
computationally predicted targets by several softwares
(TargetScan, MicroCosm and miRDB) (Figure 3B). Since
the number of differentially expressed proteins is typic-
ally much lower than the total number of predicted
targets, we looked for proteins detected in our proteomic
experiment that were also predicted as targets by the
bioinformatics studies. We identified 8 differentially ex-
pressed proteins that were also predicted by at least one of
the 3 algorithms as targets of miR-196b (Figure 3B).
Among the 8 potential targets for miR-196b, three of them
were involved in DNA (MCM4 cDNA and CTPS) or inprotein (EEF2K) synthesis and the link between these
processes and apoptosis is not clear. Similarly, AKR1B10 is
an aldo-keto reductase enzyme that acts as all-trans-
retinaldehyde reductase while LTA4H is an isoform of
leukotriene A4 hydrolase. These metabolic pathways are
most likely not involved either in regulating apoptosis.
The last two proteins (retrotransposon-derived protein
PEG10 and C22orf28) are of unknown function. We
thus chose IGF2BP1 to investigate its role in the
hypoxia-induced chemoresistance. IGF2BP1 was down-
regulated by miR-196b overexpression as revealed by
the zoom of spot 952 (Figure 3C) in the proteomic ana-
lysis as well as predicted to be a target of miR-196b by
the TargetScan software.
IGF2BP1 is a direct target of miR-196b
TargetScan 6.2 revealed 3 putative miR-196b seed match
sites present in the 3′UTR of IGF2BP1 mRNA (Figure 4A).
IGF2BP1 is a RNA-binding protein that controls the
localization, translation and/or turnover of specific target
transcripts [22]. To experimentally validate that IGF2BP1
is an endogenous target of miR-196b, HepG2 cells
were transfected with pre-miR-196b or pre-miR negative
control and the IGF2BP1 mRNA and protein levels
were measured by RT-qPCR and western blot, respectively
(Figure 4B-4C). As shown in Figure 4B, IGF2BP1 mRNA
abundance was significantly reduced by miR-196b overex-
pression compared to cells transfected with negative
control 24 and 48 h after transfection. Similarly, the abun-
dance of IGF2BP1 protein was decreased by miR-196b
overexpression when compared to pre-miR negative con-
trol 24, 48 and 72 h after the transfection (Figure 4C).
Even if miRNAs can act mainly through translational re-
pression rather than mRNA degradation, our data showed
that miR-196b regulates both IGF2BP1 mRNA and pro-
tein expression levels. These results suggest that IGF2BP1
could be a direct target of miR-196b.
To demonstrate that the negative regulatory effects of
miR-196b exerted on IGF2BP1 expression were medi-
ated through the binding of miR-196b to the predicted
sites in the 3′UTR of IGF2BP1 mRNA, a reporter plas-
mid (pmiRGLO IGF2BP1 3′UTR) containing a part of
IGF2BP1 3′UTR which includes 2 predicted binding site
Figure 3 (See legend on next page.)
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Figure 3 Proteomic analysis after miR-196b overexpression in HepG2 cells. HepG2 were transfected with pre-miR negative control or
pre-miR-196b (50 nM) during 24 h and 2D-DIGE analysis of cytosolic fraction was performed (n = 4). (A) Proteins were loaded on IPG strips
(18 cm, 3–11 non linear), followed by the second dimension on a vertical continuous 12.5% gel. Significantly down- or up-regulated proteins
(cut-off 1.2, p value < 0.05) were identified and labeled with their serial number. Arrow: spot 952/942, IGF2BP1 protein. Table shows the number
of down-regulated or up-regulated spots. (B) List of proteins identified by MS/MS analysis and predicted by softwares: TargetScan, MicroCosm
and miRDB. (C) Intensity of spot 952 was significantly lower when HepG2 cells were transfected with pre-miR-196b versus pre-miR negative
control during 24 h. Dot plots showed the variation between pre-miR negative control and pre-miR-196b for 4 replicates.
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porter plasmid, was used (Figure 4D). The reporter plas-
mid and pre-miR negative control (or pre-miR-196b)
were co-transfected in HepG2 cells. As expected, miR-
196b overexpression resulted in a significant decrease in
the luciferase reporter activity compared to cells trans-
fected with pre-miR negative control (Figure 4E). Fur-
thermore, a mutated reporter plasmid containing 3
nucleotide mutations in the miR-196b seed match sites
in the IGF2BP1 mRNA 3′UTR was used (Figure 4D). In
contrast to the wild-type reporter plasmid, miR-196b
had no significant effect on the reporter luciferase activ-
ity of the mutated plasmid, indicating that miR-196b in-
teracts directly with 3′UTR of IGF2BP1 (Figure 4E).
These results demonstrated that miR-196b directly tar-
gets the 3′UTR of IGF2BP1 mRNA leading to the
down-regulation of its expression.
Taken together, proteomic analysis, western blot, RT-
qPCR and luciferase activity data provide strong evidence
that IGF2BP1 mRNA is a direct target of miR-196b.
miR-196b overexpression has the same effects than the
IGF2BP1 down-regulation on cell proliferation and apoptosis
To study effects of IGF2BP1 down-regulation induced
by miR-196b, HepG2 cells were transfected with either
pre-miR-196b or with IGF2BP1 siRNA and cell viability,
proliferation and apoptotic profile were evaluated in nor-
mal culture conditions.
We assessed the cell morphology by phase contrast
microscopy, 72 h after pre-miR-196b or IGF2BP1 siRNA
transfection. miR-196b overexpression reduced the
cell number and floating cells were observed. On the
other hand, IGF2BP1 silencing seems to change the cell
morphology since an increase in cell size was observed
(Figure 5A).
The number of viable cells was then assessed using
a MTT assay. Results showed that the number of
untransfected cells or cells transfected with negative
controls (pre-miR negative control or RF) increased with
time, suggesting cell proliferation. miR-196b overexpres-
sion decreased significantly the number of viable cells
by 47 and 43.7%, 72 and 96 h post-transfection, respect-
ively. IGF2BP1 silencing also decreased the number
of viable cells by 51.9 and 65.2%, 72 and 96 h post-
transfection, respectively (Figure 5B).Proliferation was then directly measured by using
BrdU incorporation 72 h after transfection. Results
showed that the proliferation rate was significantly lower
when cells overexpressed miR-196b compared to cells
transfected with pre-miR negative control (33.8% inhib-
ition of cell proliferation). A significant decrease was
also observed when cells were transfected with IGF2BP1
siRNA compared to RISC Free 72 h post-transfection
(59.2% inhibition of cell proliferation) (Figure 5C).
We then assessed apoptosis by studying PARP and
caspase 3 cleavage and measuring caspase 3/7 activity
assay. As already shown in Figure 4C, miR-196b overex-
pression decreased IGF2BP1 protein abundance. In addition,
miR-196b overexpression induced an increase in PARP
cleavage 48 and 72 h post-transfection (Figure 6A, left
panel). However, even if we did not detect an increase in
caspase 3 cleavage by western blot, miR-196b overexpres-
sion induced a significant increase in caspase 3/7 activity
by 54%, 48 h post- transfection (Figure 6B). To evaluate
if IGF2BP1 is involved in the pro-apoptotic effects of
miR-196b, IGF2BP1 expression was silenced using siRNA.
As shown in Figure 6A (right panel), IGF2BP1 silencing
strongly decreased IGF2BP1 protein abundance 24, 48
and 72 h after transfection (56, 72 and 80% of inhibition,
respectively). The inhibition induced an increase in PARP
cleavage but not in caspase 3 cleavage. In parallel,
IGF2BP1 silencing induced a significant increase in cas-
pase 3/7 activity by 13% but to lower extent than the one
induced by miR-196b overexpression (Figure 6B, right
panel). These results suggest that miR-196b promoted
apoptosis and that IGF2BP1 contributes at least in part to
the pro-apoptotic action of miR-196b.
Taken together, these results showed that IGF2BP1 si-
lencing as well as miR-196b overexpression had similar
effects resulting in cell proliferation inhibition and in
apoptosis initiation in HepG2 cells.
IGF2BP1 silencing but not miR-196b overexpression
decreases myc mRNA expression
A major function of IGF2BP1 is the stabilization of nu-
merous mRNAs. Among the known IGF2BP1 target
mRNAs are actin and c-myc [23,24]. Myc represents an
interesting target because of its role as a proto-oncogene.
Furthermore, it was shown to be a target of miR-196b in
endometriotic stromal cells [25]. Finally, several studies
Figure 4 IGF2BP1 is a direct target of miR-196b in HepG2 cells. (A) The putative miR-196b targeted sequence in the igf2bp1 gene. TargetScan6.2
predicts three binding sites in IGF2BP1 3′-UTR. The alignment of the seed region of miR-196b with 3′UTR is shown. (B) Expression level of IGF2BP1
mRNA in the pre-miR-196b transfected cells determined by RT-qPCR was down-regulated in comparison to pre-miR negative control transfected
cells (pre-miR CTL-) or untransfected cells (Cells), 24 or 48 h post-transfection (means ± 1 SD, n = 3). °, °°: significantly different from untransfected cells
(p < 0.05, p < 0.01), $$$: significantly different from pre-miR negative control transfected cells (p < 0.001), for each group (N, H, NE, HE) respectively.
(C) Protein abundance of IGF2BP1 in the pre-miR-196b transfected cells determined by western blot was down-regulated in comparison to pre-miR
negative control transfected cells (pre-miR CTL-) or untransfected cells (Cells), 24, 48 and 72 h after transfection. Numbers correspond to the
quantification of the abundance of protein of interest normalized to the abundance of α-tubulin. (D) Schematic representation of the seed
region match between miR-196b and the putative IGF2BP1 3′UTR. The mutation of five nucleotides in the seed region is shown. (E) pmiRGLO
luciferase reporters containing either the wild-type or the mutant (mutated) human IGF2BP1 3′UTR were co-transfected into HepG2 cells with
pre-miR negative control or pre-miR-196b (50 nM) during 72 h. 72 h post-transfection, the cells were assayed using a dual luciferase assay.
Firefly luciferase values were normalized to Renilla luciferase values and plotted as relative luciferase activity (means ± 1 SD, n = 8).
**: significantly different from wild-type reporter (p < 0.01), ***: significantly different from pre-miR negative control transfected cells (p < 0.001).
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hancing c-myc expression [26]. Thus, the effects of
IGF2BP1 silencing and of miR-196b overexpression on
myc mRNA and protein levels were assessed in HepG2cells. IGF2BP1 silencing decreased IGF2BP1 mRNA level
by 70 and 66%, 24 and 48 h post-transfection respectively
(Figure 7A). The silencing induced an inhibition by 48% of
myc mRNA expression that was only detected 48 h after
Figure 5 Effects of miR-196b overexpression or IGF2BP1 silencing on cell morphology, viability and proliferation. HepG2 cells were
transfected either with pre-miR negative control (pre-miR CTL-) or pre-miR-196b (50 nM) either with RISC Free negative control (RF) or IGF2BP1
siRNA (50 nM). (A) 72 h after transfection, the cell morphology was observed by phase contrast microscopy. (B) Cell viability assay (MTT assay)
was performed 24, 48, 72 and 96 h after transfection of HepG2 cells (means ± 1 SD, n = 3). (C) Cell proliferation assay (BrdU ELISA assay) was performed
72 h after transfection (means ± 1 SD, n = 3). °°, °°°: significantly different from untransfected cells (Cells) (p < 0.01, p < 0.001), $$, $$$: significantly
different from pre-miR negative control transfected cells or RF negative control transfected cells (p < 0.01, p < 0.001).
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protein was decreased by IGF2BP1 silencing compared
to RF negative control 48 and 72 h after transfection
(Figure 7B). However, miR-196b overexpression did not
decrease the myc mRNA and protein levels (Figure 7C).
Taken together, results showed that miR-196b mediates
its anti-proliferative and pro-apoptotic effects through
a c-myc-independent pathway, while IGF2BP1 silencingmight exert its anti-proliferative and pro-apoptotic effects
at least in part through a c-myc-dependent pathway.
IGF2BP1 silencing does not reverse the hypoxia-induced
chemoresistance
Since we demonstrated that IGF2BP1 is a target of
miR-196b and because miR-196b was shown to modulate
hypoxia-induced chemoresistance, we sought whether the
Figure 6 Effects of miR-196b overexpression or IGF2BP1 silencing in regulation of apoptosis under normoxia. (A) HepG2 cells were
transfected with either pre-miR negative control (pre-miR CTL-) or pre-miR-196b (50 nM), either with RISC free negative control (RF) or siRNA
IGF2BP1 for 24, 48 and 72 h. IGF2BP1, cleaved PARP and cleaved caspase 3 were detected in total cell extracts by western blotting analysis, using
specific antibodies. Immunodetection of α-tubulin was used to assess the total amount of proteins loaded on the gel. Numbers correspond to
the quantification of the abundance of protein of interest normalized to the abundance of α-tubulin. (B) 48 h after transfection, the caspase
3/7 activity was assayed by measuring free AFC released from the cleavage of the caspase 3/7 substrate Ac-DEVD-AFC. Results are expressed in
fluorescence intensity, as means ± 1 SD (n = 3). °, °°°: significantly different from untransfected cells (Cells) (p < 0.05, p < 0.001), $$$: significantly
different from pre-miR negative control transfected cells (p < 0.001).
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expression inhibition. For that, HepG2 cells were
transfected with IGF2BP1 siRNA for 48 h and then
incubated under normoxia or hypoxia with or without
etoposide, and apoptotic markers were studied by
western blot (Figure 8A). IGF2BP1 silencing decreased
IGF2BP1 protein abundance in cells incubated under
normoxia or hypoxia with or without etoposide 48 h
post-transfection. However, IGF2BP1 silencing did not
modify the chemoresistance induced by hypoxia. In-
deed, no increase in PARP and caspase 3 cleavage was
observed. These data were confirmed using a caspase 3/7
activity assay that showed no modification of caspase
3/7 activity when cells were transfected with IGF2BP1
siRNA (Figure 8B).
These results indicated that IGF2BP1 silencing alone
is not sufficient to reverse the hypoxia-induced che-
moresistance probably because other miR-196b targets
could be involved.Discussion
Previously we, and others, have observed that hypoxia
protects cancer cells from the death induced by chemo-
therapies [7-10]. Our study provided new data indicating
that some of miRNAs induced/inhibited by hypoxia are
involved in chemoresistance. The most well-known of
miRNAs identified as a master regulator of hypoxia re-
sponse is miR-210 [18,20]. In this study, we confirmed
that miR-210 was up-regulated under hypoxia. Further-
more, results showed that miR-210 had an anti-
apoptotic effect. Indeed, the overexpression of miR-210
in HepG2 cells under normoxia protected HepG2 cells
from apoptosis induced by etoposide. These results are
in agreement with other studies showing that miR-210
inhibits apoptosis and protects cancer cells from cell
death [27-30].
Here, for the first time, we identified a new miRNA
down-regulated by hypoxia: miR-196b. miR-196b is a
member of the miR-196 sub-family, which comprises
Figure 7 Effects of miR-196b overexpression or IGF2BP1 silencing on c-myc mRNA expression and protein level. (A) HepG2 cells were
transfected with RISC free negative control (RF) or siRNA IGF2BP1 (50 nM) during 24 or 48 h and the mRNA expression level of IGF2BP1 was
determined by RT-qPCR (means ± 1 SD, n = 3). °, °°, °°°: significantly different from untransfected cells (Cells) (p < 0.05, p < 0.01, p < 0.001), $$$:
significantly different from RF negative control transfected cells (p < 0.001) for each group 24 or 48 h respectively. (B) HepG2 cells were
transfected with RISC free negative control (RF) or siRNA IGF2BP1 (50 nM) during 24, 48 and 72 h and the mRNA expression level and the
protein abundance of c-myc were determined by RT-qPCR and western blot respectively. (C) HepG2 cells were transfected with pre-miR negative
control (pre-miR CTL-) or pre-miR-196b (50 nM), during 24, 48 and 72 h and the mRNA expression level and the protein abundance of c-myc
were determined by RT-qPCR and western blot respectively. Numbers correspond to the quantification of the abundance of protein of interest
normalized to the abundance of α-tubulin.
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196a by one nucleotide [31]. miR-196b is associated with
some types of leukemia but very few data exist on the
role of miR-196b in solid tumors. Our results showed
that hypoxia significantly decreased miR-196b expres-
sion induced by etoposide in HepG2 cells. Several stud-
ies have demonstrated that miR-196b has a tumor
suppressive function [25,32]. Here, we demonstrated the
importance of miR-196b for modulating the hypoxia-
induced chemoresistance.
In order to understand the contribution of miR-196b
in chemoresistance induced by hypoxia, it is important
to identify its targets. It is well known that miRNAs
regulate biological processes by inhibiting gene expres-
sion by translational repression rather than mRNA deg-
radation in mammalian cells [33]. It is why we used aproteomic approach to identify new direct targets.
Among spots up- and down-regulated by miR-196b
overexpression, 172 proteins were identified. Based on
computational predictions and results obtained with a
proteomic approach, 8 proteins were identified as poten-
tial targets of miR-196b. We focused on IGF2BP1, a
member of the RNA-binding proteins [22]. Among sev-
eral functional activities, IGF2BP1 binds mRNAs, pre-
vents miRNA-mediated repression and regulates tumor
progression [34]. IGF2BP1 was identified as a target of
several miRNAs (miR-494, let-7, miR-625) [35-37]. We
have demonstrated that miR-196b overexpression signifi-
cantly decreased the mRNA and protein levels of
IGF2BP1. In order to validate that IGF2BP1 is a direct
target of miR-196b, we used luciferase activity reporters.
The results validated that miR-196b binds the 3′UTR of
Figure 8 Role of IGF2BP1 in the chemoresistance induced by
hypoxia. HepG2 cells were transfected with RISC free negative
control (RF) or siRNA IGF2BP1 (50 nM) during 48 h and then cells
were incubated under normoxia (N) or hypoxia (H) with or without
etoposide (E) (50 μM) during 16 h. (A) IGF2BP1, cleaved caspase 3
and cleaved PARP were detected in total cell extracts by western
blotting analysis, using specific antibodies. Immunodetection of
α-tubulin was used to assess the total amount of proteins loaded on
the gel. Numbers correspond to the quantification of the abundance
of protein of interest normalized to the abundance of α-tubulin
(B) 48 h after transfection, the caspase 3/7 activity was assayed by
measuring free AFC released from the cleavage of the caspase 3/7
substrate Ac-DEVD-AFC. Results are expressed in fluorescence
intensity, as means ± 1 SD (n = 3). ***: (p < 0.001), °, °°°: significantly
different from untransfected cells (Cells) (p < 0.05, p < 0.001), $$$:
significantly different from pre-miR negative control transfected cells
(p < 0.001) for each group N, H, NE, HE respectively.
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tein levels. To the best of our knowledge, this is the first
time that IGF2BP1 is shown to be a direct target of
miR-196b.
We then investigated whether IGF2BP1 is involved in
chemoresistance. Indeed, some miRNAs directly influ-
ence the sensitivity of tumor cells to anticancer agents.
Such an example is the let-7 family of miRNAs that
inhibits Bcl-xl expression and potentiates sorafenib-
induced apoptosis in human hepatocarcinoma [16].
Here, we have shown that IGF2BP1 depletion in cells
incubated under hypoxia in the presence of etoposidedid not induce apoptosis. These results indicate that
miR-196b might regulate the hypoxia-induced chemore-
sistance by the regulation of other targets than IGF2BP1
or that inhibition the expression of one protein is not
enough to recapitulate the whole effect of miR-196b.
The expression of other anti-apoptotic proteins could
be regulated by miR-196b. In addition, the overexpres-
sion of a combination of miR-196b and other miRNAs
(e.g. miR-210) in order to reverse the chemoresistance
to etoposide induced by hypoxia could be the object of
future studies.
On the other hand, miR-196b overexpression and
IGF2BP1 silencing displayed similar effects on cell pro-
liferation and apoptosis under normal culture condi-
tions, by significantly decreasing the proliferation and
inducing the apoptosis in HepG2 cells, suggesting an
anti-tumor role of the miR-196b/IGF2BP1 pathway.
These results are in agreement with recent studies per-
formed in different subtypes of cancer cells suggesting
a general mechanism of pro-apoptotic and anti-proliferative
effects of miR-196b. For example, Abe et al. have shown
that miR-196b decreased cell proliferation and induced
apoptosis in endometriotic stromal cells [25]. Yue Liu et al.
evidenced that miR-196 overexpression decreased the
proliferation in K562 cells [38]. Furthermore, miR-196b
overexpression significantly reduced cell viability, clono-
genicity, proliferation and invasion in cervical cancer [32].
In parallel to miR-196b overexpression effects, we show
that the IGF2BP1 silencing also reduced cell proliferation
and promoted apoptosis. These results are in agreement
with two recent studies. First, Mongroo et al. have shown
that the IGF2BP1 silencing plays a role in modulating cell
survival by promoting PARP and caspase 3 cleavage in
SW480 cells [39]. Secondly, a recent study showed that the
IGF2BP1 depletion by siRNA reduces the proliferation and
induces apoptosis in hepatocarcinoma cells [26]. More
interestingly, several studies reported that IGF2BP1 plays a
major role in liver carcinogenesis and in hepatocarcinoma
progression [26,37].
IGF2BP1 silencing resulted in cell morphology changes
that differ from those caused by miR-196b overexpression.
Two other works reported changes in cell morphology
upon IGF2BP1 silencing. The transient knockdown of
IGF2BP1 induced an increase in size and apparent flat-
tening of adherent HEK293 cells. Results suggested that
the shift in cell size was due to altered cytoskeletal
organization rather than an overall increase in cell mass.
In parallel, IGF2BP1 silencing was shown to decrease
mesenchymal-like cell properties by diminishing the
expression of the transcriptional regulators LEF1 and
SLUG (SNAI2). IGF2BP1 silencing also decreased cell
migration [40]. IGF2BP1 was also shown to regulate the
formation of lamellipodia and invadopodia. In osteosarcoma-
derived U2OS cells, knockdown of IGF2BP1 induced a
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of needle-like F-actin structures thus impairing cell migra-
tion. IGF2BP1 decreased the motility of these cells by
targeting mRNAs encoding MAPK4 and PTEN [41].
IGF2BP1 also targets ß-actin encoding mRNA thus regu-
lating cell adhesion and spreading [22]. The reason why
the change in cell morphology was observed upon
IGF2BP1 silencing but not caused by miR-196b overex-
pression is unclear. Two hypotheses can be proposed: ei-
ther the decrease in IGF2BP1 protein level induced by
miR-196b overexpression was not strong enough to affect
IGF2BP1 targets to a level low enough to observe its con-
sequences; or miR-196b has other mRNA targets whose
inhibition counteracts the effect of the inhibition of
IGF2BP1 expression.
IGF2BP1 has been shown to be involved in tumor de-
velopment by targeting mRNAs such as IGF2 and c-myc
[42]. In addition, several reports have described that
IGF2BP1 promotes tumor cell proliferation by enhan-
cing the expression of c-myc [26,43]. Indeed, IGF2BP1 is
a mRNA-binding protein that acts in cytoplasm by con-
trolling the localization, translation and/or turnover of
specific transcripts. For example, IGF2BP1 silencing was
shown to induce elevated degradation of c-myc mRNA
[43]. Due to fact that c-myc is a proto-oncogene, a regu-
lator of cell proliferation and apoptosis and that c-myc
is a possible target of miR-196b based on bioinformatics
algorithms [44], we decided to investigate whether c-myc
is involved in anti-proliferative and pro-apoptotic effects
of miR-196b and IGF2BP1 silencing or not. IGF2BP1
silencing reduced c-myc expression in HepG2 cells,
but no modification has been observed in response to
miR-196b overexpression. Hence, miR-196b overexpres-
sion and IGF2BP1 silencing induced anti-proliferative and
pro-apoptotic effects but these effects might be myc-
independent in cells that overexpress miR-196b. These re-
sults differ from results of Abe et al. and Bhatia et al. who
showed that miR-196b overexpression in endometriotic
cyst stromal cells [25] and in B-cell acute lymphoblastic
leukemia [44] resulted in the down-regulation of c-myc.
While the abundance of mRNA might be very different
in the cell types used in the different studies, one could
also suggest, even if all cell types are from human origin,
that the region in the 3′UTR of the mRNA, recognized
by the miR-196, might be differentially occupied by
proteins binding mRNA in these regions. The accessibility
for the miR-196 might thus be affected and thus func-
tional impact of the miR-196 on the regulation of c-myc
expression could be different in our study and results
previously published.
Taken together, these results suggest that miR-196b
anti-proliferative and pro-apoptotic effects type in nor-
mal condition culture can be myc-dependent or not, de-
pending on the cell.Conclusions
In conclusion, these results evidence the essential role of
miRNAs in chemoresistance induced by hypoxia but did
not allow the identification of a unique target able to re-
verse this chemoresistance. Indeed, considering the fact
that miRNAs can target several mRNAs simultaneously,
we further established that besides the fact that IGF2BP1
is a direct target of miR-196b, the apoptosis promoting
effect of miR-196b is not mainly through targeting
IGF2BP1. However, IGF2BP1 is a functional target of
miR-196b involved in regulating HepG2 cell viability and
proliferation in normal culture conditions.
Methods
Cell culture and hypoxia incubation
Human hepatoma HepG2 cells were maintained in cul-
ture in 75-cm2 polystyrene flasks (Costar, Lowell, MA,
USA) with D-MEM low glucose (Invitrogen, Carlsbad,
CA, USA) containing 10% of fetal calf serum (FCS)
(Invitrogen) and incubated under an atmosphere con-
taining 5% CO2. For hypoxia experiments (1% O2), cells
were incubated in serum-free CO2-independent medium
(Invitrogen, cat n°18045) supplemented with 0.5 mM
L-glutamine (Sigma, Saint Louis, USA) with or without
50 μM etoposide (Sigma). Normoxic control cells were
incubated in the same conditions but kept in normal at-
mosphere (21% O2).
TaqMan Low density array
At the end of 16 h incubation under normoxia or hyp-
oxia with or without etoposide, total RNA was extracted
from cells using the Total RNAgent extraction kit (Pro-
mega, Madison, WI, USA). mRNA contained in 2 μg
total and miRNA was reverse transcribed using the
“High Capacity cDNA Archive” kit (Applied Biosystems,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. An amount corresponding to 100 ng of
retrotranscribed total RNA in 50 μl was then mixed
with 50 μl of the “TaqMan Universal PCR master Mix”
(Applied Biosystems) and loaded into one of the 8 fill
ports the microfluidic array. “TaqMan Array Human
MicroRNA panel v1.0” (Applied Biosystems) is micro-
fluidic card that contains assays for the detection of 365
miRNAs in addition to 2 endogenous controls (RNU44
and RNU48). miRNA expression level was quantified
using the threshold cycle method [45].
Total and/or miRNA extraction
miRNA were extracted from samples containing total
RNA with TRI Reagent Solution (Invitrogen) and the
miRNeasy mini kit (Qiagen, Hilden, Germany) following
manufacturer’s instructions. Total RNA without miRNA
were extracted with RNeasy mini kit (Qiagen) following
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determined by using Nanodrop.
Reverse transcription and quantitative real-time PCR for
miRNA expression
miRNA expression was evaluated using TaqMan Micro-
RNA Assay (Applied Biosystems) as specified in manu-
facturer’s instructions. Briefly, single‑stranded cDNA was
synthesized by the TaqMan MicroRNA Reverse Transcrip-
tion Kit from 200 ng of total RNA in a 15 μl reaction. The
reactions were incubated sequentially at 16°C for 30 min,
at 42°C for 30 min and then at 85°C for 5 min. cDNAs
were then amplified by quantitative PCR in a 7900HT
Sequence Detection System using the TaqMan microRNA
Assays Human Panel sequence‑specific primers. The 20 μl
PCR included 10 μl of 2x Universal PCR Master Mix (No
AmpErase, UNG), 1 μl of each 20x TaqMan MicroRNA
Assay Mix and 1.5 μl of reverse transcription product.
The reaction mixtures were incubated in a 96‑well plates
at 95°C for 10 min, followed by 40 cycles of 15 sec at
95°C, and 1 min at 60°C. The expression level of each
miRNA was measured using the threshold cycle method
using the expression of RNU44 (endogenous control)
as reference and the expression of miRNAs under
normoxia as calibrator. All reagents were supplied by
Applied Biosystems.
Reverse transcription and quantitative real-time PCR for
total RNA
cDNA was synthesized with 2 μg of total RNA using Super-
Script II Reverse Transcriptase (Roche, Basel, Switzerland)
and random hexamers primers for IGF2BP1 gene or oli-
godT for Myc gene according to the manufacturer’s instruc-
tions. Amplification reaction assays contained 1x SYBR
Green PCR Mastermix (Applied Biosystem) and primers
(IDT, Coralville, IA, USA) at the optimal concentrations.




GCTGCACCGA-3′ [26]. The RNA expression level was
measured using the threshold cycle method [45] using
23 kDa as the normalization reference.
miRNA transfection
Chemically synthesized miRNA duplexes, called pre-
miR-210 and pre-miR-196b and negative control miRNA
(pre-miR CTL-), were purchased from Ambion (Life
Technologies, Carlsbad, CA, USA). HepG2 transfection
was performed in 6-well plates for caspase 3/7 activity
assay (50 000 cells per well) or in 25-cm2 polystyrene
flasks for protein extraction (750 000 cells per flask) with
Dharmafect 1 transfection reagent used at a 1:500
dilution (Dharmacon, Lafayette, CO, USA) and with pre-miR at a final concentration of 50 nM. Cells were incu-
bated for 24 h with transfection medium. The medium
was then replaced by fresh medium with 10% of FCS at
least 6 h before being incubated under hypoxia. Hypoxia
and/or etoposide exposure during 16 h was performed
24 or 48 h after transfection.
siRNA transfection
IGF2BP1 silencing was achieved using the following
siRNA sequence: 5′-CCGGGAGCAGACCAGGCAA
(dTdT)-3′. RISC-free (RF) siRNA purchased from Dhar-
macon was used as negative control. For siRNA experi-
ments, 750 000 cells were seeded in 25 cm2 polystyrene
flasks (Costar). The next day, cells were transfected with
50 nM siRNA using Dharmafect 1 (Dharmacon) trans-
fection reagent according to manufacturer’s instructions.
The transfection medium was removed 24 h after trans-
fection and replaced by fresh culture medium. Cells were
then incubated for 24, 48, 72 and 96 h and then incu-
bated under normoxia or hypoxia with or without etopo-
side for 16 h.
Western blot analysis
HepG2 cells, seeded in 25 cm2 flasks, were scrapped in
200 μl of lysis buffer (40 mM Tris pH 7.5, 150 mM KCl,
1 mM EDTA, 1% triton X-100) containing a protease
inhibitor mixture (« Complete » from Roche Molecular
Biochemicals, 1 tablet in 2 ml H2O, added at a 1: 10
dilution) and phosphatase inhibitors (25 mM NaVO3,
250 mM PNPP, 250 mM α-glycerophosphate and
125 mM NaF, at a 1: 10 dilution). Proteins were sepa-
rated by SDS-PAGE on 4–12% NuPAGE Bis-Tris gels
with MES or MOPS buffer (Invitrogen) and then trans-
ferred onto a low fluorescence background polyvinylidene
fluoride (PVDF) membrane (Immobilon-FL, Millipore,
Billerica, MA, USA). For fluorescence detection, mem-
branes were blocked 1 h at room temperature in Odyssey
blocking buffer (BD Biosciences, Franklin Lakes, MJ,
USA) diluted 2X in PBS and then overnight at 4°C in
Odyssey blocking buffer with 0.1% Tween containing a
specific antibody: mouse anti-PARP-1 monoclonal anti-
body (#556493 from BD Pharmingen, Franklin Lakes, MJ,
USA), rabbit anti-caspase3 antibody (#9662 from Cell
Signaling, Dancer, MA, USA), rabbit anti-IGF2BP1 anti-
body (#2852 from Cell Signaling), mouse anti-Myc (#sc-42
from SantaCruz Technologies, Dallas, TX, USA) and
mouse anti-α-tubulin monoclonal antibody (#T5168 from
Sigma-Aldrich). After 3 washes of 10 min in PBS-0.1%
Tween, the incubation with the secondary antibody (goat
anti-rabbit or anti-mouse IR Dye labelled antibody 1/7
500 dilution) (Licor, Lincoln, NE, USA,) was performed
for 1 h in Odyssey blocking buffer with 0.1% Tween
followed by 3 washes of 10 min in PBS-Tween and 2
washes in PBS. The membrane was then dried 30 min at
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(Licor). Immunodetection of α-tubulin was used as the
loading control.
Caspase-3/7 activity assay
The fluorogenic substrate Ac-DEVD-AFC (BD Pharmin-
gen) was used to measure caspase-3/7 activity according
to Lozano et al. [46]. Protein extraction and the assay
for caspase-3/7 activity were performed according to
Notte et al. [47] using 20 μg of protein extracts.
Subcellular fractionation
HepG2 cells were seeded at a density of 5 500 000 cells in
75-cm2 flasks. The next day, cells were then transfected
with pre-miR negative control or pre-miR-196b (50 nM)
for 24 h. Cells were harvested in 0.25 M saccharose con-
taining a protease inhibitor mixture (Roche Molecular
Biochemicals) and phosphatase inhibitors (25 mM NaVO3,
250 mM PNPP, 250 mM α-glycerophosphate and 125 mM
NaF, at a 1: 10 dilution) and homogenized by 5 strokes of
a B plunger in a Dounce. The homogenate was centri-
fuged for 10 min at 1 000 rpm (Labofuge 400R Heraeus
Instruments). The pellet was resuspended in 0.25 M sac-
charose and named the N (Nuclear) fraction. The super-
natant was recovered and centrifuged at 8 000 rpm
(Beckman L7-35, rotor 50 Ti) for a duration dependent on
the volume. The pellet was resuspended in 0.25 M sac-
charose and named the MLP fraction. The supernatant
was centrifuged at 35 000 rpm (Beckman L7-35, rotor 50 Ti)
for a duration dependent on the volume. The supernatant
was recovered and named the S fraction, which contains the
cytosolic proteins.
Two-dimensional electrophoresis (2-DE) analysis and
protein identification
Labeling with the cyanine dyes (GE Healthcare, Uppsala,
Sweden) was performed as described in details in the sup-
plementary methods (see Additional file 2). An amount
corresponding of 25 μg of each individual labeled samples
(pre-miR CTL-, pre-miR-196b and pooled standard sam-
ples from four replicate experiments) were mixed and
subjected to isoelectric focusing on a IPGphor isoelectric
focusing unit (GE Healthcare) along a continuous 3–11
pH gradient using IPG strips (18 cm, nonlinear 3 – 11 pH,
GE Healthcare) (details in supplementary methods, see
Additional file 2). Gels were scanned with a Typhoon
9400 imager (GE Healthcare) to detect cyanin labeled
proteins. Determination of protein spot abundance and
statistical analyses were carried out automatically using
the DeCyder 2D Differential Analysis software 6.0 (GE
Healthcare). Protein spots with more than 1.2-fold change
in volume after normalization (between pre-miR CTL-
and pre-miR-196b in the 4 replicates) and statisticallysignificant Student’s t-test (p < 0.05) were considered as
differentially abundant.
Each spot of interest was excised automatically using the
Ettan spot picking system (GE Healthcare). Detailed tryp-
sin digestion and mass spectrometry procedures by using
nanoLC-MS-MS maXis UHR-TOF (ultra-high resolution
time-of-flight) coupled with a 2D-LC Dionex UltiMate 3
000 (Bruker, Bremen, Germany) are given in the section of
the supplementary methods (see Additional file 2).
miRNA target prediction
A biocomputational approach was used based on a
stepwise guide to identify miR‑196b targets. We focused on
mRNA predicted by either TargetScan 6.2 [48], Microcosm
[49] or miRDB [50] softwares.
Reporter constructs and dual luciferase assay
The pmiRGLO plasmid vector contains cDNA sequences
encoding the Firefly luciferase (F-luc) reporter gene and
the Renilla luciferase (R-luc) gene, which acts as an in-
ternal control reporter. The pmiRGLO IGF2BP1 3′UTR
wild-type and mutated were kindly obtained from Yang
lab [51]. The wild-type 2 701-bp fragment contains two of
three putative miR-196b seed match sites (4 268 – 4
274 nt and 4 922–4 928 nt). The pmiRGLO IGF2BP1 3′
UTR mutated contains mutations at 2 sites cloned into
the pmiRGLO vector. One day before the transfection,
HepG2 cells were seeded at 30 000 cells per well into 24-
well plates. The next day, HepG2 cells were co-transfected
with 0.1 μg of pmiRGLO IGF2BP1 3′UTR wild-type or
mutated and either pre-miR negative control or pre-miR-
196b (50 nM final concentration). Transfection was
performed with Lipofectamine 2000 reagent (Invitrogen)
according to the co-transfection manufacturer’s protocol.
At 72 h post-transfection, firefly and renilla luciferase ac-
tivities were measured using Dual-luciferase Reporter
Assay System (Promega, Madison, WI, USA) according
the manufacturer’s protocol. The F-luc activity was nor-
malized to the R-luc activity.
MTT assay
The methylthiazol tetrazolium (MTT, Sigma-Aldrich)
spectrophotometric dye assay was used to detect the
number of viable cells. HepG2 cells were seeded at 20
000 cells per well into 24-well plates 24 h before trans-
fection. Cells were transfected for 24 h with either pre-
miR CTL- or pre-miR-196b (50 nM) either RISC Free
negative control (RF) or IGF2BP1 siRNA (50 nM) with
Dharmafect. 24, 48, 72 and 96 h post-transfection, cells
were incubated at 37°C for 2 h with 500 μL MTT solu-
tion (2.5 mg/mL; Sigma-Aldrich). Culture medium was
then removed and formazan crystals in the cells were
solubilized using lysis buffer (30% SDS, N,N-dimethyl-
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ance was measured at 570 nm.
BrdU ELISA kit
The BrdU Cell Proliferation ELISA kit (Roche) has been
used to measure cell proliferation according to manufac-
turer’s protocol. HepG2 cells were seeded at 2 500 cells
per well into 96-well plates. 48 h after transfection,
the BrdU solution (10 μM) was added during 24 h at
37°C. Absorbance was measured at 370 nm (reference
wavelength 492 nm).
Statistical analysis
SigmaStat software (Jandle Scientific, Germany) was
used for the statistical analysis. Data are presented as
means ± standard deviation (SD) and were evaluated by
two-way ANOVA, using the Holm-Sidak method. For
some analyses values did not follow a Gaussian distribu-
tion. In order to deal with this absence of normality,
statistical analyses were performed on log-transformed
data. In order to facilitate interpretation, untransformed
data are shown.
Additional files
Additional file 1: List of proteins in the cytosolic fraction identified
to be differentially expressed in HepG2 cells transfected with
pre-miR-196b in comparison to cells transfected with the pre-miR
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